Mauna Kea Technologies

Mauna Kea Technologies, a global medical device company headquartered in Paris, was founded in 2000 by Sacha Loiseau, who drew upon his background in astrophysics to pioneer new frontiers in medical imaging. Loiseau, a graduate of École Polytechnique with a Ph.D. in Astrophysics and Optical Instrumentation, began his career at NASA's Jet Propulsion Laboratory before applying the principles of astronomical imaging to the microscopic scale of the human body. This led to the creation of the company's flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) platform.

Cellvizio provides physicians and researchers with real-time, high-resolution cellular images of internal tissues during standard endoscopic and surgical procedures. This technology enables clinicians to visualize cellular structures, blood flow, and other micro-architectures in vivo, which can aid in the early detection and diagnosis of diseases like cancer, guide interventions, and monitor disease progression. The platform is utilized across a wide range of specialties including gastroenterology, pulmonology, and urology. The system operates via miniature, flexible microscope probes that can be introduced through the working channels of endoscopes or needles. Its next-generation models feature a smaller footprint, an intuitive touchscreen interface, and are designed for integration with robotic systems and artificial intelligence for image interpretation.

The company's business model includes the sale of Cellvizio systems and a pay-per-use (PPU) model for its consumable probes, which has been a strategic focus in the U.S. market. Mauna Kea Technologies also engages in strategic partnerships and licensing agreements with major players in the medtech and pharmaceutical industries to expand its market reach. Having received its first FDA clearance and CE mark in 2005, the company has since secured numerous additional clearances for expanded indications and technological advancements. Mauna Kea Technologies went public in July 2011, listing on the NYSE Euronext in Paris to fund its commercial expansion. The company recently initiated a safeguard procedure in France to restructure its liabilities and secure long-term funding for its development plan.

Keywords: in vivo cellular imaging, probe-based confocal laser endomicroscopy, pCLE, nCLE, medical device, endomicroscopy, optical biopsy, real-time histology, cancer diagnosis, gastroenterology imaging, pulmonology, urology, molecular imaging, fluorescence-guided surgery, medical imaging technology, Sacha Loiseau, Cellvizio, endoscopic visualization, interventional endoscopy, minimally invasive procedures, diagnostic imaging, robotic surgery integration, AI medical imaging, tissue visualization, pancreatic cysts, Barrett's esophagus